Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MBS301 in HER2+ Solid Tumors
NCT03842085Phase 1Recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Apr 2019
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MBS301 in HER2-positive solid tumor (HER2+), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Primary endpoints: Dose Limiting Toxicity at 21 days and Maximum Tolerated Dose at 21 days. Started Apr 2019; status: recruiting.
02
Drugs
MBS301
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT03842085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842085.